Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload

Autor: Einar Sjaastad Nordén, Bård Andre Bendiksen, Henriette Andresen, Kaja Knudsen Bergo, Emil Knut Espe, Almira Hasic, Ida Marie Hauge‐Iversen, Ioanni Veras, Rizwan I. Hussain, Ivar Sjaastad, Geir Christensen, Alessandro Cataliotti
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: ESC Heart Failure, Vol 8, Iss 2, Pp 918-927 (2021)
Druh dokumentu: article
ISSN: 2055-5822
DOI: 10.1002/ehf2.13177
Popis: Abstract Aims Sacubitril/valsartan (sac/val) has shown superior effect compared with blockade of the renin–angiotensin–aldosterone system in heart failure with reduced ejection fraction. We aimed to investigate effects of sac/val compared with valsartan in a pressure overload model of heart failure with preserved ejection fraction (HFpEF). Methods and results Sprague–Dawley rats underwent aortic banding or sham (n = 16) surgery and were randomized to sac/val (n = 28), valsartan (n = 29), or vehicle (n = 26) treatment for 8 weeks. Sac/val reduced left ventricular weight by 11% compared with vehicle (P = 0.01) and 9% compared with valsartan alone (P = 0.04). Only valsartan reduced blood pressure compared with sham (P = 0.02). Longitudinal early diastolic strain rate was preserved in sac/val compared with sham, while it was reduced by 23% in vehicle (P = 0.03) and 24% in valsartan (P = 0.02). Diastolic dysfunction, measured by E/e'SR, increased by 68% in vehicle (P
Databáze: Directory of Open Access Journals